ClinicalTrials.gg
TerminatedNCT00326911Updated May 25, 2011Results posted

Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer

A Phase 2 interventional study of cetuximab and bevacizumab in Metastatic Pancreatic Cancer, sponsored by Eli Lilly and Company. Terminated at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-25.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Why this study was terminated
The planned enrollment was 130 patients and the study was halted prematurely due to lack of efficacy in both arms. Enrolled patients continued treatment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 370 studies testing gemcitabine in Pancreatic Neoplasms — 30 open to participants now, 45 under way, 5 of them phase 3. Gemcitabine · Pancreatic Neoplasms.

Enrollment
106th of 353
61 · median 37
Started
2006
with 25 others
Phase 2
195 of 370
18 open now
Registered
89th of 370
by date
Lead sponsor
5 of 370
Eli Lilly and Company

Among the 370 studies testing gemcitabine in Pancreatic Neoplasms, this one is the 106th largest by enrollment of the 353 interventional ones that give a count, is one of 26 that started in 2006, is one of 195 in phase 2, and was the 89th registered.

Pancreatic Neoplasms

3,902 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

30 of the 370 studies testing gemcitabine in Pancreatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

25 more — sign in →

By country, each count listing its studies:

All 30 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 370 studies testing gemcitabine in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

Eligible patients with metastatic pancreatic cancer will be treated with dual agent monoclonal antibody consisting of cetuximab and bevacizumab alone or in combination with gemcitabine

03

Conditions studied

  • Metastatic Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has provided signed written .
  • The patient is ≥18 years of age.
  • The patient has or cytologically-confirmed pancreatic adenocarcinoma not amenable to curative treatment with surgery or has documented or suspected extrapancreatic .
  • The patient has either (a) as defined by Version 1.0 (RECIST) or (b) non-measurable disease with an elevated baseline CA19-9 level (≥2 x the [ULN]).
  • The patient's (ECOG) performance status is ≤2.
  • The patient has adequate hematologic function as defined by an (ANC) ≥1500/mm3 and a count ≥100,000/mm3 obtained within 2 weeks prior to the first dose of study medication.
  • The patient has adequate hepatic function as defined by a total ≤2.0 mg/dL and transaminases ≤5.0 x ULN obtained within 2 weeks prior to the first dose of study medication.
  • The patient has adequate renal function as defined by serum creatinine ≤2.0 x ULN and urine dipstick for proteinuria ≤1+ obtained within 2 weeks prior to the first dose of study medication. If urine dipstick is ≥2+, then a 24-hour urine for protein must demonstrate \< 1000 mg of protein in 24 hours to allow participation in the study. Urinalysis is also acceptable.
  • If the patient is on full-dose anticoagulation therapy (eg, warfarin or low molecular weight [LMW] heparin), the following criteria must be met:

    • The patient has an in-range ([INR]usually between 2 and 3) on a stable dose of oral anticoagulant or be on a stable dose of LMW heparin
    • The patient has no active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)
  • If the patient is not on full-dose anticoagulation therapy, the following criteria must be met:

    • The patient has adequate coagulation function as defined by INR ≤1.5
    • The patient has a partial thromboplastin (PTT) ≤ULN obtained within 2 weeks prior to the first dose of study medication
  • If a woman, the patient agrees to use an accepted and effective method of (hormonal or barrier methods, abstinence) prior to study entry and for the duration of the study. If a male and sexually active, the patient agrees to use effective contraception.
  • The patient is accessible for treatment and follow-up. Patients enrolled in this trial must be treated at the participating center.

Exclusion criteria

Exclusion Criteria:

  • Endocrine tumors or lymphoma of the pancreas
  • Known
  • Prior therapy with an epidermal growth factor receptor (EGFR) inhibitor or vascular endothelial growth factor (VEGF) inhibitor
  • Prior chemotherapy, hormonal therapy, or radiation therapy for advanced pancreatic cancer, patients who received chemotherapy and/or radiation therapy in the setting will be eligible as long as the adjuvant therapy was completed >6 months prior
  • Concurrent other than non-melanomatous skin cancer or carcinoma in situ of the cervix
  • Concurrent treatment with other anti-cancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, radiotherapy, chemoembolization, or targeted therapy
  • Ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations
  • History of arterial thrombotic events within 9 months
  • History of uncontrolled hypertension (>150/100 mmHg) not on a stable regimen of anti-hypertensive therapy
  • History of significant bleeding events or upper or lower gastrointestinal bleeding within 9 months
  • History of gastrointestinal perforation within 12 months
  • Serious non-healing wound ulcer, bone fracture, or major surgical procedure with 28 days
  • If a woman, is pregnant or lactating
  • An employee of the investigator or study center as well as family members of the employees
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    cetuximab + bevacizumab + gemcitabine

    Cetuximab 400 mg/m2 weekly (over 120 minutes) on day 1 of cycle 1 with subsequent weekly infusions of 250 mg/m2 (over 60 minutes), followed by bevacizumab 10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks, and gemcitabine 1000 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks. All medications will be administered by intravenous infusion on the same day. The order of study drug administration will be cetuximab, bevacizumab, and gemcitabine. On day 1 of cycle 1, one hour must elapse between administration of cetuximab and bevacizumab.

    Biological: cetuximab · Biological: bevacizumab · Drug: gemcitabine

  • Active comparator
    cetuximab + bevacizumab

    Cetuximab 400 mg/m2 weekly (over 120 minutes) on day 1 of cycle 1 with subsequent weekly infusions of 250 mg/m2 (over 60 minutes), followed by bevacizumab 10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks. Both medications will be administered by intravenous infusion on the same day. The order of study drug administration will be cetuximab and bevacizumab. On day 1 of cycle 1, one hour must elapse between administration of cetuximab and bevacizumab.

    Biological: cetuximab · Biological: bevacizumab

Interventions

  • Biologicalcetuximab

    I.V. infusion of 400 mg/m2 (over 120 minutes) on day 1 of cycle 1

    Also known as: Erbitux®

  • Biologicalbevacizumab

    10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks.

    Also known as: Avastin®

  • 1000 mg/m2 administered intravenously at 10 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks.

    Also known as: Gemzar®

  • Biologicalcetuximab

    I.V.infusions of 250 mg/m2 (over 60 minutes) weekly

    Also known as: Erbitux®

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    Progression-free survival is the time from randomization until the date of progressive disease (PD) or death from any cause whichever is first reported. Patients who die without a reported prior progression were considered to have progresssed on the day of their death. Patients who did not progress were censored at the day of their last tumor assessment.

    Time frame: Time from randomization to disease progression or death from any cause (Range: 0 -10 months)

Secondary outcomes

  1. Overall Survival (OS)

    This measure is defined as the time from randomization to the date of death due to any cause. Survival of living patients or those who lost to follow-up were censored on the last date the patients were known to be alive.

    Time frame: Survival information was collected continuously every 3 months after completion of therapy and/or follow-up (range: 1-19 months).

  2. The Number of Patients With a Best Overall Response of Either a Complete Response (CR) or Partial Response (PR)

    The best overall response is the number of patients with a best overall response of CR or PR, as classifed by the investigator according to the RECIST guidelines. A CR is the disappearance of all target lesions and a PR is at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum longest diameter.

    Time frame: Tumor evaluations were performed every 8 weeks while on cetuximab therapy until PD or recurrence. Patients with a PR or CR had a confirmatory tumor assessment no less than 4 weeks after the initial evaluation.

  3. Percentage of Patients With Carbohydrate Antigen 19-9 (CA19-9) Response at End of Cycle 2 in Patients With Elevated Baseline Values (Equal or Greater Than 2 x Upper Limit of Normal).

    CA19-9 is a tumor marker for pancreatic cancer and the level usually increases as the disease is progressing. The CA19-9 response was the percentage of patients whose CA19-9 level was declining, stable or increasing \< 10% compared with baseline, divided by the total patients with elevated baseline CA19-9 in that arm.

    Time frame: First day of treatment to the end of Cycle 2, Week 1

  4. Time to Progression (TTP)

    Time to progression was defined as the time from randomization until the date of objectively confirmed tumor progression was first reported. The censoring rule was consistent with PFS except death. Patients who died from any cause were censored at the time of death or at last tumor assessment date if the death date was missing. For patients lost to follow-up, they were censored at the last tumor assessment date.

    Time frame: Time from randomization until the date of objective tumor progression was first reported (range: 11 -38 months)

  5. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Reported AEs per patient were coded according to the corresponding preferred term and system organ class in the Medical Dictionary for regulatory Activities dictionary. The National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3.0 was used to grade all AEs. The collection of AEs began at the time the patient received the first cetuximab dose and continued during the study until 30 days after the last dose of cetuximab. All patients who were enrolled and treated with cetuximab were assessed for safety (mITT population, as treated).

    Time frame: An AE was included in the safety analysis if its onset date occurred anytime during cetuximab treatment or up to 30 days after the last dose of cetuximab.

  6. Change From Baseline in Quality of Life (QoL) Assessment Using the Linear Analog Scale Assessment (LASA), Overall QoL at Cycle 2 Week 4

    Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Overall QoL question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.

    Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up

  7. Change From Baseline in QoL Assessment Using LASA, Overall Mental Well Being, at Cycle 2 Week 4

    Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Overall Mental Well Being question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.

    Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up

  8. Change From Baseline in QoL Assessment Using LASA, Overall Physical Well Being, at Cycle 2 Week 4

    Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Overall Physical Well Being question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.

    Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up

  9. Change From Baseline in QoL Assessment Using LASA, Overall Emotional Well Being, at Cycle 2 Week 4

    Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Overall Emotional Well Being question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.

    Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up

  10. Change From Baseline in QoL Assessment Using LASA, Level of Social Activity, at Cycle 2 Week 4

    Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Level of Social Activity question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.

    Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up

  11. Change From Baseline in QoL Assessment Using LASA, Overall Spiritual Well Being, at Cycle 2 Week 4

    Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Overall Spiritual Well Being question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.

    Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up while receiving study drug

  12. Change From Baseline in QoL Assessment Using LASA, Frequency of Pain, at Cycle 2 Week 4

    Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Frequency of Pain question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates improvement from baseline.

    Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up

  13. Change From Baseline in QoL Assessment Using LASA, Severity of Pain, Average, at Cycle 2 Week 4

    Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Severity of Pain question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A positive score indicates improvement from baseline.

    Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up while receiving study drug

  14. Change From Baseline in QoL Assessment Using LASA, Level of Fatigue, Average, at Cycle 2 Week 4

    Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Level of Fatigue question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A positive score indicates improvement from baseline.

    Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up

  15. Change From Baseline in QoL Assessment Using LASA, Level of Support, Friends and Family, at Cycle 2 Week 4

    Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Level of Support, Friends and Family question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.

    Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up

  16. Change From Baseline in QoL Assessment Using LASA, Financial Concerns, at Cycle 2 Week 4

    Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Financial Concerns Question question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.

    Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up

  17. Change From Baseline in QoL Assessment Using LASA, Legal Concerns, at Cycle 2 Week 4

    Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Legal Concerns question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.

    Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up

  18. Change From Baseline in Assessment of Pain Using the Brief Pain Inventory (BPI) Short Form, Worst Pain, at Cycle 2 Week 4

    Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. Analysis of pain using the BPI was considered exploratory. The Worst Pain (change from baseline) to Cycle 2 Week 4 is reported. The worst pain is 10 and no pain is 0. A negative score indicates improvement from baseline.

    Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up

  19. Change From Baseline in Assessment of Pain Using BPI Short Form, Least Pain, at Cycle 2 Week 4

    Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. Analysis of pain using the BPI was considered exploratory. The Least Pain (change from baseline) to Cycle 2 Week 4 is reported. The worst pain is 10 and no pain is 0. A negative score indicates improvement from baseline.

    Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up

  20. Change From Baseline in Assessment of Pain Using BPI Short Form, Average Pain, at Cycle 2 Week 4

    Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. Analysis of pain using the BPI was considered exploratory. The Average Pain (change from baseline) to Cycle 2 Week 4 is reported. The worst pain was 10 and no pain is 0. A negative score indicates improvement from baseline.

    Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up

  21. Change From Baseline in Assessment of Pain Using BPI Short Form, Pain Right Now, at Cycle 2 Week 4

    Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. Analysis of pain using the BPI was considered exploratory. The Pain Right Now question (change from baseline) to Cycle 2 Week 4 is reported. The worst pain is 10 and no pain is 0. A negative score indicates improvement from baseline.

    Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up

  22. Change From Baseline in Assessment of Pain Using BPI Short Form, Interference, at Cycle 2 Week 4

    Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. Analysis of pain using the BPI was considered exploratory. The Interference question (change from baseline) to Cycle 2 Week 4 is reported. Complete interference is scored as 10 and no interference is scored as 0. A negative score indicates improvement from baseline.

    Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up

07

Results

Posted Dec 4, 2009
Limitations and caveats
Accrual on the trial was stopped earlier than planned due to insufficient efficacy in both arms.

Participant flow

Patients were recruited from a population of pancreatic cancer patients treated at investigational centers.

Participant flow — Overall Study
MilestoneCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Started3031
Completed2929
Not completed12
Withdrew: Hospitalization prior to treatment01
Withdrew: Physician decision prior to treatment10
Withdrew: Withdrawal by subject prior to treatment01

Outcome measures

PrimaryProgression-free Survival (PFS)

Progression-free survival is the time from randomization until the date of progressive disease (PD) or death from any cause whichever is first reported. Patients who die without a reported prior progression were considered to have progresssed on the day of their death. Patients who did not progress were censored at the day of their last tumor assessment.

Time frame:
Time from randomization to disease progression or death from any cause (Range: 0 -10 months)
Reported as:
Median · months
Progression-free Survival (PFS)
monthsCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Progression-free Survival (PFS)3.55 (2.00 to 5.59)1.91 (1.81 to 2.76)
SecondaryOverall Survival (OS)

This measure is defined as the time from randomization to the date of death due to any cause. Survival of living patients or those who lost to follow-up were censored on the last date the patients were known to be alive.

Time frame:
Survival information was collected continuously every 3 months after completion of therapy and/or follow-up (range: 1-19 months).
Reported as:
Median · Months
Overall Survival (OS)
MonthsCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Overall Survival (OS)5.41 (3.84 to 6.74)4.17 (2.69 to 8.74)
SecondaryThe Number of Patients With a Best Overall Response of Either a Complete Response (CR) or Partial Response (PR)

The best overall response is the number of patients with a best overall response of CR or PR, as classifed by the investigator according to the RECIST guidelines. A CR is the disappearance of all target lesions and a PR is at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum longest diameter.

Time frame:
Tumor evaluations were performed every 8 weeks while on cetuximab therapy until PD or recurrence. Patients with a PR or CR had a confirmatory tumor assessment no less than 4 weeks after the initial evaluation.
Reported as:
Number · Participants
The Number of Patients With a Best Overall Response of Either a Complete Response (CR) or Partial Response (PR)
ParticipantsCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
The Number of Patients With a Best Overall Response of Either a Complete Response (CR) or Partial Response (PR)4 (3.9 to 31.7)0 (0.1 to 17.8)
SecondaryPercentage of Patients With Carbohydrate Antigen 19-9 (CA19-9) Response at End of Cycle 2 in Patients With Elevated Baseline Values (Equal or Greater Than 2 x Upper Limit of Normal).

CA19-9 is a tumor marker for pancreatic cancer and the level usually increases as the disease is progressing. The CA19-9 response was the percentage of patients whose CA19-9 level was declining, stable or increasing \< 10% compared with baseline, divided by the total patients with elevated baseline CA19-9 in that arm.

Time frame:
First day of treatment to the end of Cycle 2, Week 1
Reported as:
Number · Percentage of participants
Percentage of Patients With Carbohydrate Antigen 19-9 (CA19-9) Response at End of Cycle 2 in Patients With Elevated Baseline Values (Equal or Greater Than 2 x Upper Limit of Normal).
Percentage of participantsCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Percentage of Patients With Carbohydrate Antigen 19-9 (CA19-9) Response at End of Cycle 2 in Patients With Elevated Baseline Values (Equal or Greater Than 2 x Upper Limit of Normal).89
SecondaryTime to Progression (TTP)

Time to progression was defined as the time from randomization until the date of objectively confirmed tumor progression was first reported. The censoring rule was consistent with PFS except death. Patients who died from any cause were censored at the time of death or at last tumor assessment date if the death date was missing. For patients lost to follow-up, they were censored at the last tumor assessment date.

Time frame:
Time from randomization until the date of objective tumor progression was first reported (range: 11 -38 months)
Reported as:
Median · months
Time to Progression (TTP)
monthsCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Time to Progression (TTP)4.11 (2.17 to 5.95)2.07 (1.84 to 4.01)
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Reported AEs per patient were coded according to the corresponding preferred term and system organ class in the Medical Dictionary for regulatory Activities dictionary. The National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3.0 was used to grade all AEs. The collection of AEs began at the time the patient received the first cetuximab dose and continued during the study until 30 days after the last dose of cetuximab. All patients who were enrolled and treated with cetuximab were assessed for safety (mITT population, as treated).

Time frame:
An AE was included in the safety analysis if its onset date occurred anytime during cetuximab treatment or up to 30 days after the last dose of cetuximab.
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)2929
SecondaryChange From Baseline in Quality of Life (QoL) Assessment Using the Linear Analog Scale Assessment (LASA), Overall QoL at Cycle 2 Week 4

Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Overall QoL question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.

Time frame:
Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Reported as:
Mean · Scores on a scale
Change From Baseline in Quality of Life (QoL) Assessment Using the Linear Analog Scale Assessment (LASA), Overall QoL at Cycle 2 Week 4
Scores on a scaleCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Change From Baseline in Quality of Life (QoL) Assessment Using the Linear Analog Scale Assessment (LASA), Overall QoL at Cycle 2 Week 4-0.9 ± 2.9-0.9 ± 2.3
SecondaryChange From Baseline in QoL Assessment Using LASA, Overall Mental Well Being, at Cycle 2 Week 4

Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Overall Mental Well Being question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.

Time frame:
Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Reported as:
Mean · Scores on a scale
Change From Baseline in QoL Assessment Using LASA, Overall Mental Well Being, at Cycle 2 Week 4
Scores on a scaleCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Change From Baseline in QoL Assessment Using LASA, Overall Mental Well Being, at Cycle 2 Week 40.6 ± 2.0-0.8 ± 1.4
SecondaryChange From Baseline in QoL Assessment Using LASA, Overall Physical Well Being, at Cycle 2 Week 4

Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Overall Physical Well Being question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.

Time frame:
Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Reported as:
Mean · Scores on a scale
Change From Baseline in QoL Assessment Using LASA, Overall Physical Well Being, at Cycle 2 Week 4
Scores on a scaleCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Change From Baseline in QoL Assessment Using LASA, Overall Physical Well Being, at Cycle 2 Week 4-0.6 ± 3.1-0.6 ± 1.7
SecondaryChange From Baseline in QoL Assessment Using LASA, Overall Emotional Well Being, at Cycle 2 Week 4

Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Overall Emotional Well Being question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.

Time frame:
Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Reported as:
Mean · Scores on a scale
Change From Baseline in QoL Assessment Using LASA, Overall Emotional Well Being, at Cycle 2 Week 4
Scores on a scaleCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Change From Baseline in QoL Assessment Using LASA, Overall Emotional Well Being, at Cycle 2 Week 4-0.2 ± 2.8-1.1 ± 2.1
SecondaryChange From Baseline in QoL Assessment Using LASA, Level of Social Activity, at Cycle 2 Week 4

Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Level of Social Activity question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.

Time frame:
Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Reported as:
Mean · Scores on a scale
Change From Baseline in QoL Assessment Using LASA, Level of Social Activity, at Cycle 2 Week 4
Scores on a scaleCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Change From Baseline in QoL Assessment Using LASA, Level of Social Activity, at Cycle 2 Week 4-1.1 ± 2.90.6 ± 2.3
SecondaryChange From Baseline in QoL Assessment Using LASA, Overall Spiritual Well Being, at Cycle 2 Week 4

Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Overall Spiritual Well Being question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.

Time frame:
Screening, and then every 8 weeks while receiving study drug to 30-day follow-up while receiving study drug
Reported as:
Mean · Scores on a scale
Change From Baseline in QoL Assessment Using LASA, Overall Spiritual Well Being, at Cycle 2 Week 4
Scores on a scaleCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Change From Baseline in QoL Assessment Using LASA, Overall Spiritual Well Being, at Cycle 2 Week 4-0.4 ± 1.8-0.3 ± 1.1
SecondaryChange From Baseline in QoL Assessment Using LASA, Frequency of Pain, at Cycle 2 Week 4

Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Frequency of Pain question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates improvement from baseline.

Time frame:
Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Reported as:
Mean · Scores on a scale
Change From Baseline in QoL Assessment Using LASA, Frequency of Pain, at Cycle 2 Week 4
Scores on a scaleCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Change From Baseline in QoL Assessment Using LASA, Frequency of Pain, at Cycle 2 Week 4-1.5 ± 2.9-2.3 ± 2.6
SecondaryChange From Baseline in QoL Assessment Using LASA, Severity of Pain, Average, at Cycle 2 Week 4

Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Severity of Pain question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A positive score indicates improvement from baseline.

Time frame:
Screening, and then every 8 weeks while receiving study drug to 30-day follow-up while receiving study drug
Reported as:
Mean · Scores on a scale
Change From Baseline in QoL Assessment Using LASA, Severity of Pain, Average, at Cycle 2 Week 4
Scores on a scaleCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Change From Baseline in QoL Assessment Using LASA, Severity of Pain, Average, at Cycle 2 Week 4-0.5 ± 2.8-0.9 ± 2.4
SecondaryChange From Baseline in QoL Assessment Using LASA, Level of Fatigue, Average, at Cycle 2 Week 4

Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Level of Fatigue question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A positive score indicates improvement from baseline.

Time frame:
Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Reported as:
Mean · Scores on a scale
Change From Baseline in QoL Assessment Using LASA, Level of Fatigue, Average, at Cycle 2 Week 4
Scores on a scaleCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Change From Baseline in QoL Assessment Using LASA, Level of Fatigue, Average, at Cycle 2 Week 41.5 ± 2.30.3 ± 2.6
SecondaryChange From Baseline in QoL Assessment Using LASA, Level of Support, Friends and Family, at Cycle 2 Week 4

Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Level of Support, Friends and Family question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.

Time frame:
Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Reported as:
Mean · Scores on a scale
Change From Baseline in QoL Assessment Using LASA, Level of Support, Friends and Family, at Cycle 2 Week 4
Scores on a scaleCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Change From Baseline in QoL Assessment Using LASA, Level of Support, Friends and Family, at Cycle 2 Week 40.1 ± 1.3-0.8 ± 1.5
SecondaryChange From Baseline in QoL Assessment Using LASA, Financial Concerns, at Cycle 2 Week 4

Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Financial Concerns Question question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.

Time frame:
Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Reported as:
Mean · Scores on a scale
Change From Baseline in QoL Assessment Using LASA, Financial Concerns, at Cycle 2 Week 4
Scores on a scaleCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Change From Baseline in QoL Assessment Using LASA, Financial Concerns, at Cycle 2 Week 4-0.1 ± 2.40.9 ± 3.7
SecondaryChange From Baseline in QoL Assessment Using LASA, Legal Concerns, at Cycle 2 Week 4

Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Legal Concerns question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.

Time frame:
Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Reported as:
Mean · Scores on a scale
Change From Baseline in QoL Assessment Using LASA, Legal Concerns, at Cycle 2 Week 4
Scores on a scaleCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Change From Baseline in QoL Assessment Using LASA, Legal Concerns, at Cycle 2 Week 40.4 ± 1.72.3 ± 3.2
SecondaryChange From Baseline in Assessment of Pain Using the Brief Pain Inventory (BPI) Short Form, Worst Pain, at Cycle 2 Week 4

Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. Analysis of pain using the BPI was considered exploratory. The Worst Pain (change from baseline) to Cycle 2 Week 4 is reported. The worst pain is 10 and no pain is 0. A negative score indicates improvement from baseline.

Time frame:
Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Reported as:
Mean · Scores on a scale
Change From Baseline in Assessment of Pain Using the Brief Pain Inventory (BPI) Short Form, Worst Pain, at Cycle 2 Week 4
Scores on a scaleCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Change From Baseline in Assessment of Pain Using the Brief Pain Inventory (BPI) Short Form, Worst Pain, at Cycle 2 Week 4-1.2 ± 2.80.5 ± 2.5
SecondaryChange From Baseline in Assessment of Pain Using BPI Short Form, Least Pain, at Cycle 2 Week 4

Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. Analysis of pain using the BPI was considered exploratory. The Least Pain (change from baseline) to Cycle 2 Week 4 is reported. The worst pain is 10 and no pain is 0. A negative score indicates improvement from baseline.

Time frame:
Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Reported as:
Mean · Scores on a scale
Change From Baseline in Assessment of Pain Using BPI Short Form, Least Pain, at Cycle 2 Week 4
Scores on a scaleCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Change From Baseline in Assessment of Pain Using BPI Short Form, Least Pain, at Cycle 2 Week 4-0.4 ± 2.00.9 ± 2.4
SecondaryChange From Baseline in Assessment of Pain Using BPI Short Form, Average Pain, at Cycle 2 Week 4

Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. Analysis of pain using the BPI was considered exploratory. The Average Pain (change from baseline) to Cycle 2 Week 4 is reported. The worst pain was 10 and no pain is 0. A negative score indicates improvement from baseline.

Time frame:
Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Reported as:
Mean · Scores on a scale
Change From Baseline in Assessment of Pain Using BPI Short Form, Average Pain, at Cycle 2 Week 4
Scores on a scaleCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Change From Baseline in Assessment of Pain Using BPI Short Form, Average Pain, at Cycle 2 Week 4-0.6 ± 1.8-0.2 ± 2.1
SecondaryChange From Baseline in Assessment of Pain Using BPI Short Form, Pain Right Now, at Cycle 2 Week 4

Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. Analysis of pain using the BPI was considered exploratory. The Pain Right Now question (change from baseline) to Cycle 2 Week 4 is reported. The worst pain is 10 and no pain is 0. A negative score indicates improvement from baseline.

Time frame:
Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Reported as:
Mean · Scores on a scale
Change From Baseline in Assessment of Pain Using BPI Short Form, Pain Right Now, at Cycle 2 Week 4
Scores on a scaleCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Change From Baseline in Assessment of Pain Using BPI Short Form, Pain Right Now, at Cycle 2 Week 4-0.9 ± 2.60.9 ± 2.0
SecondaryChange From Baseline in Assessment of Pain Using BPI Short Form, Interference, at Cycle 2 Week 4

Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. Analysis of pain using the BPI was considered exploratory. The Interference question (change from baseline) to Cycle 2 Week 4 is reported. Complete interference is scored as 10 and no interference is scored as 0. A negative score indicates improvement from baseline.

Time frame:
Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Reported as:
Mean · Scores on a scale
Change From Baseline in Assessment of Pain Using BPI Short Form, Interference, at Cycle 2 Week 4
Scores on a scaleCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Change From Baseline in Assessment of Pain Using BPI Short Form, Interference, at Cycle 2 Week 4-0.2 ± 2.30.8 ± 2.9

Adverse events

Collected over Adverse events were collected beginning at the time the patient received the initial cetuximab infusion and continued throughout the study until 30 days after the last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cetuximab + Bevacizumab + Gemcitabine—21/29 (72.4%)29/29 (100%)
Cetuximab + Bevacizumab—16/29 (55.2%)29/29 (100%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Disease progressionGeneral disorders5/299/29
Pulmonary embolismRespiratory, thoracic and mediastinal disorders6/292/29
Abdominal PainGastrointestinal disorders4/291/29
VomitingGastrointestinal disorders1/294/29
NauseaGastrointestinal disorders2/293/29
Gastrointestinal HaemorrhageGastrointestinal disorders1/292/29
DiarrhoeaGastrointestinal disorders0/292/29
FatigueGeneral disorders2/290/29
Urinary tract infectionInfections and infestations2/291/29
CellulitisInfections and infestations2/290/29
Most frequent other events
Showing 10 of 74
Most frequent other events
EventCetuximab + Bevacizumab + GemcitabineCetuximab + Bevacizumab
Acneiform dermatitisRespiratory, thoracic and mediastinal disorders22/2921/29
FatigueGeneral disorders20/2910/29
NauseaGastrointestinal disorders14/2914/29
AnorexiaMetabolism and nutrition disorders13/299/29
VomitingGastrointestinal disorders11/299/29
ConstipationCardiac disorders11/297/29
AnemiaBlood and lymphatic system disorders9/291/29
NeutropeniaBlood and lymphatic system disorders9/290/29
ThrombocytopeniaBlood and lymphatic system disorders9/290/29
StomatitisGastrointestinal disorders9/297/29

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cetuximab + Bevacizumab + GemcitabineCetuximab + BevacizumabTotal
<=18 years000
Between 18 and 65 years181836
>=65 years121325
Age Continuous
Age Continuous(years)Cetuximab + Bevacizumab + GemcitabineCetuximab + BevacizumabTotal
Mean62.7 ± 11.662.2 ± 11.462.4 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)Cetuximab + Bevacizumab + GemcitabineCetuximab + BevacizumabTotal
Female111526
Male191635
Region of Enrollment
Region of Enrollment(participants)Cetuximab + Bevacizumab + GemcitabineCetuximab + BevacizumabTotal
United States303161
08

Study locations

16 sites
  • ImClone Investigational Site
    Jonesboro, Arkansas 72401, United States
  • ImClone Investigational Site
    San Francisco, California 94115, United States
  • ImClone Investigational Site
    Stamford, Connecticut 06902, United States
  • ImClone Investigational Site
    Miami, Florida 33176, United States
  • ImClone Investigational Site
    Orlando, Florida 32804, United States
  • ImClone Investigational Site
    Orlando, Florida 32806, United States
  • ImClone Investigational Site
    Atlanta, Georgia 30309, United States
  • ImClone Investigational Site
    Augusta, Georgia 30901, United States
  • ImClone Investigational Site
    Marietta, Georgia 30060, United States
  • ImClone Investigational Site
    Metairie, Louisiana 70006, United States
  • ImClone Investigational Site
    Billings, Montana 59101, United States
  • ImClone Investigational Site
    Concord, North Carolina 28025, United States
  • ImClone Investigational Site
    Philadelphia, Pennsylvania 19106, United States
  • ImClone Investigational Site
    Charleston, South Carolina 29406, United States
  • ImClone Investigational Site
    Arlington, Texas 76012, United States
  • ImClone Investigational Site
    Dallas, Texas 75230, United States
09

References and documents

Publications

  • Ko AH, Youssoufian H, Gurtler J, Dicke K, Kayaleh O, Lenz HJ, Keaton M, Katz T, Ballal S, Rowinsky EK. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs. 2012 Aug;30(4):1597-606. doi: 10.1007/s10637-011-9691-8. Epub 2011 Jun 1. PubMed 21629990 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Oct 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2006
First posted
May 17, 2006
Start
May 2006
Primary completionActual
Oct 2008
CompletionActual
Dec 2008
Results first posted
Dec 4, 2009
Last update
May 25, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00326911
First posted
May 17, 2006
Start date
May 2006
Primary completion
Oct 2008
Completion
Dec 2008
Results posted
Dec 4, 2009
Last update
May 25, 2011

Study contacts

E-mail: ClinicalTrials@ ImClone.com
study chair · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemcitabine

Start the discussion